A Phase I Clinical Trial of mTOR Inhibition With Rapamycin for Enhancing Intranodal Dendritic Cell Vaccine Induced Anti-Tumor Immunity In Patients With NY-ESO-1 Expressing Solid Tumors
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Cancer vaccine NY-ESO-1 (Primary) ; Sirolimus
- Indications Bladder cancer; Brain cancer; Gastrointestinal cancer; Liver cancer; Lung cancer; Malignant melanoma; Oesophageal cancer; Ovarian cancer; Prostate cancer; Renal cancer; Sarcoma; Solid tumours; Uterine cancer
- Focus Adverse reactions
- 04 Oct 2016 Biomarkers information updated
- 11 Oct 2013 Planned number of patients changed from 20 to 30 as reported by ClinicalTrials.gov.
- 28 Aug 2012 Planned number of patients changed from 30 to 20.